$251 Thousand is the total value of Knott David M Jr's 153 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 142.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Apollo Global Management, Inc. | $17,282 | – | 225,000 | +100.0% | 6.88% | – | |
| ISEE | Buy | IVERIC bio, Inc. | $3,423 | +116.5% | 87,000 | +33.8% | 1.36% | +119.3% |
| SGEN | Buy | Seagen Inc. | $3,176 | +213.8% | 16,500 | +230.0% | 1.26% | +217.6% |
| SNY | New | Sanofi | $3,018 | – | 56,000 | +100.0% | 1.20% | – |
| MCRB | Buy | Seres Therapeutics, Inc. | $2,251 | +26.0% | 470,000 | +49.2% | 0.90% | +27.6% |
| ALKS | New | Alkermes PLC | $2,097 | – | 67,000 | +100.0% | 0.84% | – |
| Buy | Aadi Bioscience, Inc. | $1,785 | +34.2% | 261,000 | +42.1% | 0.71% | +35.8% | |
| Buy | Arcellx Inc | $1,265 | +46.6% | 40,000 | +42.9% | 0.50% | +48.4% | |
| INZY | Buy | Inozyme Pharma, Inc. | $1,225 | +33.6% | 220,000 | +37.5% | 0.49% | +35.6% |
| CHRS | New | Coherus Biosciences, Inc. | $1,046 | – | 245,010 | +100.0% | 0.42% | – |
| New | FaZe Holdings Inc. WTS | $671 | – | 58,321 | +100.0% | 0.27% | – | |
| New | Syros Pharmaceutical, Inc | $303 | – | 96,260 | +100.0% | 0.12% | – | |
| XOMA | Buy | XOMA Corporation | $283 | -1.0% | 15,000 | +10.9% | 0.11% | +0.9% |
| FSK | New | FS KKR Capital Corp. | $219 | – | 11,425 | +100.0% | 0.09% | – |
| AKRO | New | Akero Therapeutics, Inc. | $94 | – | 2,000 | +100.0% | 0.04% | – |
| New | Leap Therapeutics, Inc. | $90 | – | 28,730 | +100.0% | 0.04% | – | |
| New | Linde PLC | $27 | – | 70 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Calumet Specialty Products Partners, LP | 11 | Q2 2024 | 31.5% |
| Alphabet Inc-Cl C | 11 | Q2 2024 | 8.2% |
| DocGo, Inc. | 11 | Q2 2024 | 5.8% |
| Ligand Pharmaceuticals Incorporated | 11 | Q2 2024 | 4.3% |
| Pfizer Inc. | 11 | Q2 2024 | 3.2% |
| JPMorgan Chase & Co. | 11 | Q2 2024 | 1.7% |
| Avadel Pharmaceuticals plc | 11 | Q2 2024 | 2.0% |
| Viking Therapeutics, Inc. | 11 | Q2 2024 | 2.9% |
| Vertex Pharmaceuticals, Inc. | 11 | Q2 2024 | 2.1% |
| AllianceBernstein Holdings PL Unit LTD | 11 | Q2 2024 | 0.9% |
View Knott David M Jr's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| MIDWEST HOLDING INC.Sold out | December 22, 2023 | 0 | 0.0% |
| Calumet Specialty Products Partners, L.P. | November 08, 2021 | 4,292,200 | 5.4% |
View Knott David M Jr's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-12 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 4 | 2023-12-22 |
| SC 13D/A | 2023-12-22 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
View Knott David M Jr's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.